Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment

Reuters

02 Jun

<a href="https://laohu8.com/S/RLAY">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment

Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival $(PFS)$ of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2540089762"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540089762\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540089762?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540089762","market":"us","top_or_hot":-1,"title":"Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRelay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-02 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/RLAY\">Relay Therapeutics</a> Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Relay <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival <a href=\"https://laohu8.com/S/PFS\">$(PFS)$</a> of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BGHQF748.EUR","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDLNQVCH:1","article_id":"2540089762","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540089762","pubTimestamp":1748862036,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology  2025 Annual Meeting, the data demonstrates a median progression-free survival  of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated co","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4563":"昨日强势股","BK4139":"生物科技","BK4588":"碎股","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","RLAY":"Relay Therapeutics","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC"},"translate_title":"Relay Therapeutics宣布启动RLY-2608治疗乳腺癌的3期ReDiscover-2研究","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"RLAY":0.9},"content_text":"Relay Therapeutics Announces Launch of Phase 3 ReDiscover-2 Study for RLY-2608 in Breast Cancer Treatment\n    \n\n        Relay Therapeutics Inc., a clinical-stage precision medicine company, has announced updated interim clinical data for their investigational drug RLY-2608. Presented at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting, the data demonstrates a median progression-free survival $(PFS)$ of 11.0 months in second-line patients with PI3Kα-mutated, HR+, HER2- metastatic breast cancer who were treated with RLY-2608 in combination with fulvestrant. The company also announced plans to initiate a Phase 3 trial, named ReDiscover-2, in mid-2025. This trial will focus on patients with similar cancer profiles. Relay Therapeutics continues to explore next-generation triplet combinations involving atirmociclib and ribociclib. Further details on the data and upcoming trials are available on the company's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Relay Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9461430-en) on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}